All In Biotech

NDA 213478 · Nobelpharma

Hyftor

Sirolimus · Topical · mTOR Inhibitor Immunosuppressant; Kinase Inhibitor

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Mar 22, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,853

224 Phase 3, 143 recruiting

FAERS reports

13,673

11,686 serious, 2,174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 22, 2025.

HYFTOR is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. ( 1 )

Mechanism: The mechanism of action of sirolimus in the treatment of angiofibroma associated with tuberous sclerosis is unknown. Tuberous sclerosis is associated with genetic defects in TSC1 and TSC2 which leads to the constitutive activation of mammalian target of rapamycin (mTOR). Sirolimus inhibits mTOR activation.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 22, 2022 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
  • HYFTOR · SIROLIMUS 0.2% · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sirolimus" as an intervention, any sponsor and status, largest first.

All 1,853 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,127
  • drug ineffective1,149
  • product use in unapproved indication792
  • pyrexia533
  • diarrhoea530
  • pneumonia501
  • drug interaction450
  • acute kidney injury443
  • thrombotic microangiopathy386
  • transplant rejection384
  • cytomegalovirus infection355
  • condition aggravated320

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200441
200553
200651
2007232
2008194
2009294
2010152
2011253
2012231
2013204
2014239
2015315
2016425
2017598
2018845
2019990
20201,021
20211,054
20221,230
20231,170
20241,489
20251,583
20261,009

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Hyftor (Sirolimus)

2024 spending

$1.4M

Beneficiaries

81

375 claims

Per beneficiary

$17,136

$183.60 per unit

View as table
YearSpending
2020$0
2021$0
2022$108,684
2023$916,135
2024$1,388,023

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,786 on PubMed

Sponsor: Nobelpharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.